Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

about

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

Item

http://www.wikidata.org/entity/Q57130345

description

wetenschappelijk artikel

@nl

name

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@en

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@nl

type

Item

label

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@en

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@nl

prefLabel

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@en

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@nl

P1476

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

@en

P2093

David Khayat

http://www.w3.org/2001/XMLSchema#string

Jean Baptiste Bachet

http://www.w3.org/2001/XMLSchema#string

Maria Angeles Gil-Delgado

http://www.w3.org/2001/XMLSchema#string

Naima Mahi

http://www.w3.org/2001/XMLSchema#string

Olivier Lucidarme

http://www.w3.org/2001/XMLSchema#string

P2860

Peliosis hepatis: Personal experience and literature review

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Clinical advances in the development of novel VEGFR2 inhibitors.

Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 tri

The role of tumour microenvironment in gastric cancer angiogenesis.

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

P304

532-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1159/000490906

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P698

30283289

http://www.w3.org/2001/XMLSchema#string

P921

gastroesophageal junction adenocarcinoma

adenocarcinoma

P932

6167727

http://www.w3.org/2001/XMLSchema#string